Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Making sense of antisense.

Laura Vidal1, Sarah Blagden, Gerhardt Attard

  • 1Centre for Cancer Therapeutics, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, London, United Kingdom.

European Journal of Cancer (Oxford, England : 1990)
|November 18, 2005
PubMed
Summary

Antisense oligonucleotides (ASOs) show promise for targeting genes inaccessible to other therapies. Further development requires combination strategies and novel formulations to optimize cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer.

Nature·2026
Same author

ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

Molecular cancer research : MCR·2026
Same author

Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.

Nature communications·2026
Same author

Targeting oncogenic TβRI signaling inhibits androgen-independent prostate cancer growth and metastasis.

Signal transduction and targeted therapy·2026
Same author

A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.

Investigational new drugs·2026

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Targeted gene therapies, including small molecules and antibodies, have advanced cancer treatment.
  • Antisense oligonucleotides (ASOs) offer a potential approach for targeting genes resistant to conventional therapies.
  • The latest generation of ASOs demonstrates safety and efficacy in modulating protein expression in clinical settings.

Purpose of the Study:

  • To review the clinical experience with antisense oligonucleotides (ASOs) as targeted cancer therapies.
  • To identify critical issues and future directions for the optimal development of ASO therapeutics.
  • To explore the potential of ASOs and short interfering RNA (siRNA) in cancer treatment.

Main Methods:

  • Review of clinical data and literature on antisense oligonucleotide (ASO) applications in cancer therapy.
  • Analysis of challenges and opportunities for ASO development, including combination strategies and drug delivery.
  • Discussion of emerging RNA interference (RNAi) therapeutics like short interfering RNA (siRNA).

Main Results:

  • Antisense oligonucleotides (ASOs) can effectively target previously undruggable genes in cancer.
  • Current ASO technology is safe and well-tolerated, with proven ability to reduce target protein levels.
  • Short interfering RNA (siRNA) therapeutics are emerging as a complementary approach in early clinical trials.

Conclusions:

  • Future clinical studies should investigate ASO combinations to overcome target redundancy and enhance efficacy.
  • Development of novel drug delivery systems, such as subcutaneous formulations, is needed to improve ASO treatment duration and patient compliance.
  • Addressing manufacturing costs is crucial for the broader success of ASO and siRNA therapeutics in oncology.

Related Experiment Videos